Srdjan Stankovic Selected Research

pimavanserin

1/2022	Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe.
1/2021	Trial of Pimavanserin in Dementia-Related Psychosis.
1/2021	Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients.
1/2021	Erratum to: HARMONY Study: Pimavanserin Significantly Prolongs Time to Relapse of Dementia-Related Psychosis.
12/2020	Effect of Adjunctive Pimavanserin on Sleep/Wakefulness in Patients With Major Depressive Disorder: Secondary Analysis From CLARITY.
11/2020	Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study.
11/2020	Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: A post hoc analysis.
1/2020	Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis.
1/2020	Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson's Disease Psychosis.
1/2019	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY).

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Srdjan Stankovic Research Topics

Disease

7	Psychotic Disorders (Schizoaffective Disorder) 01/2021 - 01/2018
6	Hallucinations (Hallucination) 01/2021 - 01/2018
5	Schizophrenia (Dementia Praecox) 01/2022 - 08/2015
4	Parkinson Disease (Parkinson's Disease) 01/2021 - 01/2018
3	Urinary Tract Infections (Urinary Tract Infection) 01/2021 - 01/2018
3	Major Depressive Disorder (Major Depressive Disorders) 12/2020 - 01/2019
2	Dementia (Dementias) 01/2021 - 01/2021
2	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2021 - 12/2020
2	Headache (Headaches) 01/2021 - 01/2019
2	Sleepiness 12/2020 - 03/2016
2	Alzheimer Disease (Alzheimer's Disease) 11/2020 - 01/2018
1	Toothache (Toothaches) 01/2022
1	Constipation 01/2021
1	Edema (Dropsy) 01/2021
1	Nausea 01/2019
1	Body Weight (Weight, Body) 11/2016
1	Weight Gain 11/2016
1	Psychomotor Agitation (Akathisia) 03/2016

Drug/Important Bio-Agent (IBA)

11	pimavanserinIBA 01/2022 - 01/2018
5	Antipsychotic Agents (Antipsychotics)IBA 01/2021 - 08/2015
4	aripiprazole lauroxilIBA 12/2017 - 08/2015
1	Pharmaceutical PreparationsIBA 01/2021
1	Antidepressive Agents (Antidepressants)IBA 12/2020
1	Adenosine Diphosphate (ADP)IBA 11/2020
1	5-HT2A Serotonin Receptor (5 HT2A Receptor)IBA 01/2018
1	TabletsIBA 01/2018
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 11/2016
1	LipidsIBA 11/2016
1	ProlactinIBA 11/2016
1	Blood Glucose (Blood Sugar)IBA 11/2016

Therapy/Procedure

3	Injections 12/2017 - 08/2015
2	Home Nursing (Nursing, Home) 11/2020 - 01/2018
1	Aftercare (After-Treatment) 01/2022
1	Therapeutics 01/2019
1	Intramuscular Injections 08/2015